ArticleInternational journal of clinical and experimental pathology2018

Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.

Yonghua Shi et al.PubMed ↗Full text ↗

No numbers read from the abstract.